

Product Name: Tariquidar Revision Date: 01/10/2021

Product Data Sheet

HN

Tariquidar

Cat. No.:	A8208
CAS No.:	206873-63-4
Formula:	C38H38N4O6
M.Wt:	646.73
Synonyms:	XR9576, XR 9576, XR-9576,Tariquidar
Target:	Membrane Transporter/Ion Channel
Pathway:	P-gp
Storage:	Store at -20°C
	810

Solvent & Solubility

	insoluble in H2O; ins	insoluble in H2O; insoluble in EtOH; \geq 16.17 mg/mL in DMSO				
In Vitro	Preparing Stock Solutions	Mass Solvent Concentration	1mg	5mg	10mg	
	Stock Solutions	1 mM	1.5462 mL	7.7312 mL	15.4624 mL	
	018	5 mM	0.3092 mL	1.5462 mL	3.0925 mL	
	PENN	10 mM	0.1546 mL	0.7731 mL	1.5462 mL	

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	P-glycoprotein inhibitor, potent and non-competitive		
IC ₅₀ & Target	5.1 nM (Kd) (P-glycoprotein)		
	Cell Viability Assay	Part	
	Cell Line:	KB-3-1, KB-8-5-11 (ABCB1-expressing variant), MCF-7, MCF-7/VP16 (ABCC1-expressing variant), H460, H460/MX20 (ABCG2-expressing variant)	
In Vitro	Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.	

1 | www.apexbt.com

	Reacting conditions:	≥ 100 nM
	Applications:	At concentrations ≥ 100 nM, tariquidar inhibited both P-gp and BCRP but did
		not inhibit MRP1. Accumulation of the fluorescent substrate calcein-AM in
		ABCB1-expressing cells treated with 100 nM and 1 μM tariquidar increased
		14-fold and 19-fold, respectively. Most P-gp was inhibited at 100 nM. At the
	APEABIO	same concentrations, tariquidar also increased the accumulation of the
	of the second seco	fluorescent substrate mitoxantrone in ABCG2-expressing cells by 4-fold
	all a constant	(P<0.001) and 8-fold (P<0.001), respectively. These data indicate that
	ALC .	tariquidar inhibits both transporters with similar potency because at 100 nM, it
		restored accumulation to 56% of control for P-gp and 84% of control for BCRP.
		Tariquidar did not increase accumulation of substrate in ABCC1-expressing
		cells.
	Animal experiment	
	Animal models:	NMRI nu/nu mice
	Dosage form:	Oral administration, 0.1 ml/10 g of body weight
	Applications:	The ABCB1 modulator tariquidar affects the distribution of paclitaxel in nude
	and and	mice. In the brains, Co-application of tariquidar with paclitaxel led to a
		comparable increase in the brain concentration of the cytostatic by a factor of
In Vivo		2.5-to 6.7. In liver, no statistically significant differences were determined
		between the different ABCB1 modulator group and the control group. In the
		kidneys, the paclitaxel content in kidney decreased to achieve concentrations
		similar to those in the untreated control group.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may
	0	slightly differ with the theoretical value. This is caused by an experimental
	E Para	system error and it is normal.

Product Citations

 Mohammadpour R, Safarian S, Buckway B, Ghandehari H. "Comparative EndocytosisMechanisms and Anticancer Effect of HPMA Copolymer- and PAMAM Dendrimer-MTCPConjugates for Photodynamic Therapy." Macromol Biosci. 2016 Oct 25.PMID:27779358
Sajja, Ravi K., and Luca Cucullo. "Altered glycaemia differentially modulates efflux transporter expression and activity in hCMEC/D3 cell line." Neuroscience letters 598 (2015): 59-65.PMID:25982326

See more customer validations on www.apexbt.com.

References

[1] Kannan P, Telu S, Shukla S, et al. The "specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS chemical neuroscience, 2010, 2(2): 82-89.

[2] Hubensack M, Müller C, Höcherl P, et al. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. Journal of cancer research and clinical oncology, 2008, 134(5): 597-607.

2 | www.apexbt.com

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APExBIO Technology www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com







